AbbVie Receives Additional Approval for Rinvoq as Treatment for Polyarticular Juvenile Idiopathic Arthritis

AbbVie’s Rinvoq Gains Approval for Polyarticular Juvenile Idiopathic Arthritis in Japan

AbbVie, a leading biopharmaceutical company, has announced that it has received additional regulatory approval in Japan for its medication, Rinvoq (upadacitinib), to be used specifically for treating polyarticular juvenile idiopathic arthritis (pcJIA). This approval marks a significant milestone in AbbVie’s ongoing commitment to addressing unmet medical needs within the pediatric autoimmune disease landscape.

Understanding Polyarticular Juvenile Idiopathic Arthritis (pcJIA)

Juvenile idiopathic arthritis (JIA) is a chronic inflammatory disorder characterized by persistent arthritis in children aged 16 or younger, lasting for more than six weeks without any identifiable cause. Among various subtypes of JIA, pcJIA accounts for approximately 30% of all JIA cases. This condition typically involves multiple joints, leading to symptoms like limping, morning stiffness, reduced physical activity, joint swelling, and difficulty performing fine motor tasks. Unfortunately, more than 45% of pcJIA patients may continue to experience active disease into adulthood, greatly impacting their quality of life and limiting physical function.

Rinvoq – A Novel Treatment Option

Rinvoq is classified as a Janus kinase (JAK) inhibitor and was previously approved in Japan for nine indications, including rheumatoid arthritis and atopic dermatitis. The latest approval allows Rinvoq to be prescribed to patients over the age of two, expanding the treatment modalities available for managing pcJIA. Rinvoq is administered orally once daily. In addition, a new formulation of the product will be made available in liquid form, allowing for dose adjustments based on the patient's weight, thus enhancing treatment personalization.

Explanatory Remarks from AbbVie’s President

Tiago Campos Rodrigues, President of AbbVie Japan, commented on the significance of this approval, stating, "pcJIA can profoundly impact the daily lives of both patients and their families. The approval of Rinvoq tablet and the newly added liquid formulation in Japan provides a new treatment option for many patients suffering from this condition. With the introduction of the liquid formulation, we can now better meet the diverse needs of pcJIA patients. AbbVie remains committed to tackling the unmet needs in the realm of immune disorders, striving for improved outcomes for each individual patient."

Research Foundations for Approval

The recent regulatory approval was based on outcomes from the international multicenter phase 1 trial, known as M15-340. This trial evaluated Rinvoq's efficacy and safety in treating patients with pcJIA who did not achieve adequate response with existing therapies.

Following this approval, Rinvoq now ranks as the ninth indication approved in Japan, joining a list that includes several autoimmune conditions such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis.

Rinvoq Product Overview

Rinvoq tablets are available in various dosages, including 45mg, 30mg, 15mg, and 7.5mg, along with the new liquid formulation at 0.1% (1mg/mL). The standard treatment protocol involves:
- For pcJIA:
- Age 2 and above, weight-based dosing:
- 10kg to <20kg: 3mL (3mg) twice daily
- 20kg to <30kg: 4mL (4mg) twice daily
- ≥30kg: 15mg once daily or 6mL (6mg) twice daily.

AbbVie’s Mission and Commitment

AbbVie’s mission is centered on addressing significant health challenges through the innovative creation of pharmaceuticals and solutions. The company aims to foster enhanced lives across various therapeutic domains, including immune disorders, oncology, neurological disorders, eye care, and aesthetic medical products through its Allergan aesthetics portfolio. To learn more about AbbVie’s efforts, visit AbbVie Japan Website.

Rinvoq represents a pivotal advancement for patients battling pcJIA, offering a new avenue for treatment that could profoundly improve their quality of life. The expansion of treatment options signifies progress in the management of complex autoimmune conditions in younger populations. As AbbVie continues to innovate, the future looks promising for children and families affected by pcJIA.